China (Mainland)
- Product Details
Keywords
- Febuxostat
- 144060-53-7
- C16H16N2O3S
Quick Details
- ProName: Febuxostat
- CasNo: 144060-53-7
- Molecular Formula: C16H16N2O3S
- Appearance: powder
- Application: PharmaIntermediate
- DeliveryTime: within 3-7 day
- PackAge: As required
- Port: shanghai or other
- ProductionCapacity: 5 Metric Ton/Month
- Purity: 99%
- Storage: keep in dry and cool condition
- Transportation: by sea or by air
- LimitNum: 100 Gram
Superiority
Changzhou Xuanming Chemical Co., Ltd. is dedicated to the technology development, manufacturing, import and export chemicals, which are specialized in pharmaceutical intermediates, pesticide intermediate, industry of fine chemicals and custom synthesis. Now, we enjoy good reputation among customers and take favorable market share in domestic and at abroad.
Changzhou Xuanming Chemical CO., LTD is located in Northern Jiangshu Industry Park, we have modern manufacture bases and some laboratories, which can supply the key intermediate for your projects, and short your synthesis scheme and supply you a reference compound for bioassay or a high purity analytical standard. We have been abided by “treat technology as first, quality as basis, customers as God, and be honest and sincere”. It is our final aim to provide environmental and high technological products and meet customers’ requirements according to keep effors on developing new chemical fields.
Changzhou Xuanming Chemical CO., LTD promises to help you with heart and soul.
Details
| Febuxostat Basic information |
| Product Name: | Febuxostat |
| Synonyms: | Febuxostat (Uloric);FBX;Uloric;Febuxostat (TEI-6720);Febuxostat Tablets;FEBUXOSTAT API;Febuxostat (This product is unavailable in the U.S.);Febuxostat Tabletshehe |
| CAS: | 144060-53-7 |
| MF: | C16H16N2O3S |
| MW: | 316.37 |
| EINECS: | 682-158-6 |
| Product Categories: | zjh;API;Febuxostat;TRILIPIX;Other APIs;eterocycles;-;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol File: | 144060-53-7.mol |
|
|
|
| Febuxostat Chemical Properties |
| Melting point | 238-239°(dec.) |
| storage temp. | Refrigerator |
| form | powder |
| Merck | 14,3948 |
| CAS DataBase Reference | 144060-53-7(CAS DataBase Reference) |
| Safety Information |
| RTECS | XJ3675310 |
| Febuxostat Usage And Synthesis |
| Indications and Usage | Febuxostat is a new generation xanthine oxidase inhibitor developed by Tejin Co. (Japan,) used clinically for for long-term treatment of hyperuicemia (gout,) a new and highly effective non-purine selective inhibitor of xanthine oxidase. It is not recommended for gout patients without hyperuricemia. |
| Mechanisms of Action | The production of uric acid in the body is related to purine metabolism. In the last step of the production, hypoxanthine produces xanthine through the action of xanthine oxidoreductase (XOR), finally producing uric acid. Inhibiting the activity of this enzyme can effectively reduce the production of uric acid. Xanthine oxidase is the main enzyme promoting uric acid production. Through highly selective inhibition of oxidized and reduced xanthine oxidase, Febuxostat can reduce synthesis of uric acid, decreasing its concentration and effectively treating gout . Through liver metabolism, Xanthine oxidase does not rely on renal excretion, so patients with moderate to severe liver and kidney dysfunction do not need to reduce dosages. Febuxostat is a non-purine XOR inhibitor, so it is very safe. |
| Description |
Febuxostat, a selective xanthine oxidase inhibitor, was launched for the chronic management of hyperuricemia in patients with gout. Hyperuricemia is defined as a serum uric acid concentration exceeding the limit of solubility. It predisposes affected persons to gout, a disease characterized by the formation of crystals of monosodium urate or uric acid from supersaturated fluids in joints and other tissues. Crystal deposition is asymptomatic, but it is revealed by bouts of joint inflammation. If left untreated, further crystals accumulate in joints and can form deposits known as tophi. A major aim in gout management is the long-term reduction of serum uric acid concentrations below saturation levels, as this results in crystal dissolution and eventual disappearance. Febuxostat is a nonpurine derivative with higher potency and selectivity than allopurinol for inhibiting xanthine oxidase. It completely inhibits human xanthine oxidase activity in the lung cancer cell line A549, whereas the activities of other enzymes involved in purine or pyrimidine metabolism (e.g., purine nucleoside phosphorylase, adenosine deaminase, and pyrimidine nucleoside phosphorylase) are affected by <4%. The incidence of adverse events such as dizziness, diarrhea, headache, and nausea with febuxostat was similar to allopurinol. Febuxostat is contraindicated in patients being treated with the xanthine oxidase substrates such as azathioprine, mercaptopurine, and theophylline. Febuxostat can be synthesized in a multistep sequence from 2,4-dicyanophenol, starting with the alkylation of the phenolic hydroxyl group with isobutyl bromide and potassium carbonate, followed by treatment with thioacetamide in hot dimethyl formamide to yield 3-cyano-4-isobutoxythiobenzamide. Cyclization of the thioamide group with 2-chloroacetoacetic acid ethyl ester in refluxing ethanol affords 2-(3-cyano-4-isoutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester, which is hydrolyzed with sodium hydroxide to produce febuxostat. |
| Chemical Properties | Crystalline Solid |
| Originator | Teijin (Japan) |
| Uses | antihyperlipidemic |
| Uses | Xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout. |
| Uses | Febuxostat is primarily indicated in conditions like Gout, Hyperuricemia |
| Brand name | Uloric, Adenuric |
